United States Patent
US Patent 7846457: Cosmetic use of botulinum toxin for the treatment…
US 7846457 · granted 2010-12-07
Abstract
A method of temporarily elevating the eyebrow position and softening undesirable glabellar muscle activity to affect a more desirable appearance. In a broad aspect the invention comprises injecting small quantities of botulinum toxin (BTX) equivalent in activity to 0.001 to 1.0 Units of botulinum toxin A, dissolved in 10 to 50 microliters microdroplets of injectable saline carrier, and injected 0.5 to 1.0 millimeters below the skin surface to treat the septal and orbital orbicularis oculi muscles, on each side of a patient's face. In sufficient numbers, injected microdroplets of BTX are able to selectively weaken these muscles. This method preferably also includes using microdroplets of BTX to treat: a) the depressor supercilii muscle, on each side; b) the procerus muscle; c) the corrugator supercilii muscle, on each side; and d) the inferior limit of the frontalis muscle where it meets the superior aspect of the orbital portion of the orbicularis oculi muscle.
| Patent Number | 7846457 |
|---|---|
| Title | Cosmetic use of botulinum toxin for the treatment of eyebrow and forehead ptosis, and unwanted eyebrow expression |
| Filed | 2006-05-04 |
| Granted | 2010-12-07 |
| Inventor(s) | Steinsapir; Kenneth D. |
| CPC Classification | A61K 39/08, A61K 39/02, A61K 39/00, A61K 38/00 |
| Number of Claims | 14 |
Abstract
A method of temporarily elevating the eyebrow position and softening undesirable glabellar muscle activity to affect a more desirable appearance. In a broad aspect the invention comprises injecting small quantities of botulinum toxin (BTX) equivalent in activity to 0.001 to 1.0 Units of botulinum toxin A, dissolved in 10 to 50 microliters microdroplets of injectable saline carrier, and injected 0.5 to 1.0 millimeters below the skin surface to treat the septal and orbital orbicularis oculi muscles, on each side of a patient's face. In sufficient numbers, injected microdroplets of BTX are able to selectively weaken these muscles. This method preferably also includes using microdroplets of BTX to treat: a) the depressor supercilii muscle, on each side; b) the procerus muscle; c) the corrugator supercilii muscle, on each side; and d) the inferior limit of the frontalis muscle where it meets the superior aspect of the orbital portion of the orbicularis oculi muscle.
Claim 1
A method of temporarily elevating the eyebrow position and softening undesirable glabellar muscle activity to effect a more desirable appearance, comprising:injecting botulinum toxin (BTX) dissolved in microdroplets of injectable saline carrier to treat the septal and orbital orbicularis oculi muscles, on each side of a patient's face, wherein said botulinum toxin (BTX) comprises doses of 0.001 to 1.0 Unitequivalents of Clostridum botulinum toxin A; wherein said doses of BTX are dissolved in 0.01 to 0.05 ml microdroplets of injectable saline carrier; wherein said microdroplets of BTX solution are injected 0.5 to 1.0 millimeters below the skin surfacewhere the muscles of facial expression responsible for eyebrow and glabellar depression insert into the skin; wherein said injected microdroplets of BTX are distributed over the muscles of facial expression responsible for eyebrow and glabellardepression including the septal and orbital orbicularis oculi muscles, and the inferior portion of the frontalis muscles where they insert into the skin at the level of the eyebrows; wherein the total number of microdroplets of botulinum toxin areadjusted to achieve the desired degree of muscle we
Claims
14 totalA method of temporarily elevating the eyebrow position and softening undesirable glabellar muscle activity to effect a more desirable appearance, comprising:injecting botulinum toxin (BTX) dissolved in microdroplets of injectable saline carrier to treat the septal and orbital orbicularis oculi muscles, on each side of a patient's face, wherein said botulinum toxin (BTX) comprises doses of 0.001 to 1.0 Unitequivalents of Clostridum botulinum toxin A; wherein said doses of BTX are dissolved in 0.01 to 0.05 ml microdroplets of injectable saline carrier; wherein said microdroplets of BTX solution are injected 0.5 to 1.0 millimeters below the skin surfacewhere the muscles of facial expression responsible for eyebrow and glabellar depression insert into the skin; wherein said injected microdroplets of BTX are distributed over the muscles of facial expression responsible for eyebrow and glabellardepression including the septal and orbital orbicularis oculi muscles, and the inferior portion of the frontalis muscles where they insert into the skin at the level of the eyebrows; wherein the total number of microdroplets of botulinum toxin areadjusted to achieve the desired degree of muscle we